# US 2025/0152593 A1 · p38 MAPK INHIBITORS AND USES THEREOF

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152593 A1
- Document ID: US20250152593A1
- Status: Published application
- Kind: A1
- Application number: 18/941,810
- Filed: 2024-11-08
- Published: 2025-05-15
- Earliest claimed: 2023-11-10
- Assignees: City of Hope; National and Kapodistrian University of Athens
- Applicants: City of Hope; National and Kapodistrian University of Athens
- Inventors: Sangkil Nam; Hannah Zhang; Steven Rosen; Ioannis K. Kostakis; Alexios Leandros Skaltsounis; Eleftheria A. Georgiou
- Web page: https://patentgrep.com/patent/US20250152593A1

## CPC

- A61K 31/519: ortho- or peri-condensed with heterocyclic rings
- A61K 31/167: having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
- A61K 38/15: Depsipeptides; Derivatives thereof
- C07D 471/04: Ortho-condensed systems
- C07D 487/04: Ortho-condensed systems
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Described herein, inter alia, are p38 MAPK inhibitors and uses thereof.

## Claims

### Claim 1

A compound, or a pharmaceutically acceptable salt thereof, having the formula:
wherein
Ring A is cycloalkyl, heterocycloalkyl, aryl, or heteroaryl;
L1 is —NR10C(O)— or —C(O)NR10—;
L4 is a bond, —C(O)—, —C(O)O—, —OC(O)—, —O—, —S—, —NR40—, —C(O)NR40—,
—NR40C(O)—, —NR40C(O)O—, —OC(O)NR40—, —NR40C(O)NR40A—, —S(O)2—, —NR40S(O) 2—,
—S(O)2NR40—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;
R1 is independently halogen, —CX13, —CHX12, —CH2X1, —OCX13, —OCH2X1,
—OCHX12, —CN, —SOn1R1D, —SOv1NR1AR1B, —NR1CNR1AR1B, —ONR1AR1B, —NR1CC(O)NR1AR1B, —N(O)m1, —NR1AR1B, —C(O)R1C, —C(O)OR1C, —OC(O)R1C, —OC(O)OR1C, —C(O)NR1A R1B,
—OC(O)NR1AR1B, —OR1D, —SR1D, —NR1ASO2R1D, —NR1AC(O)R1C, —NR1AC(O)OR1C, —NR1AOR1C,
—SF5, —N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R2 is independently halogen, —CX23, —CHX22, —CH2X2, —OCX23, —OCH2X2,
—OCHX22, —CN, —SOn2R2D, —SOv2NR2AR2B, —NR2CNR2AR2B, —ONR2AR2B, —NR2CC(O)NR2AR2B,
—N(O)m2, —NR2AR2B, —C(O)R2C, —C(O)OR2C, —OC(O)R2C, —OC(O)OR2C, —C(O)NR2AR2B,
—OC(O)NR2AR2B, —OR2D, —SR2D, —NR2ASO2R2D, NR2AC(O)R2C, —NR2AC(O)OR2C, —NR2AOR2C,
—SF5, —N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R3 is hydrogen, —CCl3, —CBr3, —CF3, —CI3, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CHC12,
—CHBr2, —CHF2, —CHI2, —CN, —OH, —NH2, —COOH, —CONH2, —OCCl3, —OCBr3, —OCF3, —OCI3,
—OCH2Cl, —OCH2Br, —OCH2F, —OCH2I, —OCHCl2, —OCHBr2, —OCHF2, —OCHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R4 is hydrogen, halogen, —CX43, —CHX42, —CH2X4, —OCX43, —OCH2X4, —OCHX42,
—CN, —SOn4R4D, —SOv4NR4AR4B, —NR4cNR4AR4B, —ONR4AR4B, —NHC(O)NR4AR4B, N(O)m4,
—NR4AR4B, —C(O)R4C, —C(O)OR4C, —C(O)NR4AR4B, —OR4D, —SR4D, —NR4ASO2R4D, NR4AC(O)R4C, —NR4AC(O)OR4C, —NR4AOR4C, —SF5, —N3, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R10, R40, and R40A are independently hydrogen, —CCl3, —CBr3, —CF3, —CI3, —CH2Cl,
—CH2Br, —CH2F, —CH2I, —CHCl2, —CHBr2, —CHF2, —CHI2, —CN, —OH, —NH2, —COOH, —CONH2,
—OCCl3, —OCBr3, —OCF3, —OCI3, —OCH2Cl, —OCH2Br, —OCH2F, —OCH2I, —OCHCl2, —OCHBr2,
—OCHF2, —OCHI2, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;
R1A, R1B, R1C, R1D, R2A, R2B, R2C, R2D, R4A, R4B, R4C, and R4D are independently hydrogen, —CCI3, —CBr3, —CF3, —CI3, —CHCl2, —CHBr2, —CHF2, —CHI2, —CH2Cl, —CH2Br, —CH2F, —CH2I, —CN, —OH, —NH2, —COOH, —CONH2, —OCCl3, —OCF3, —OCBr3, —OCI3, —OC HCl2, —OCHBr2, —OCHI2, —OCHF2, —OCH2Cl, —OCH2Br, —OCH2J, —OCH2F, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; R1A and R1B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R2A and R2B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl; R4A and R4B substituents bonded to the same nitrogen atom may optionally be joined to form a substituted or unsubstituted heterocycloalkyl or substituted or unsubstituted heteroaryl;
z1 is an integer from 0 to 7;
z2 is an integer from 0 to 4;
X1, X2, and X4 are independently —Cl, —Br, —I, or —F;
n1, n2, and n4 are independently an integer from 0 to 4; and
m1, m2, m4, v1, v2, and v4 are independently 1 or 2.

### Claim 2 (depends on 1)

The compound of claim 1, having the formula:

### Claim 3 (depends on 1)

The compound of claim 1, having the formula:

### Claim 4 (depends on 1)

The compound of claim 1, wherein Ring A is phenyl or 5 to 6 membered heteroaryl.

### Claim 5 (depends on 1)

The compound of claim 1, wherein R1 is independently halogen, —CF3, —CHF2, —CH2F, —NH2, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2 to 8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocycloalkyl, substituted or unsubstituted C6-C10 aryl, or substituted or unsubstituted 5 to 10 membered heteroaryl.

### Claim 6 (depends on 1)

The compound of claim 1, wherein R1 is independently —CF3, —N(CH3)2, or unsubstituted morpholinyl.

### Claim 7 (depends on 1)

The compound of claim 1, wherein is

### Claim 8 (depends on 1)

The compound of claim 1, wherein R2 is independently halogen, —CF3, —CHF2, —CH2F, —NH2, substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2 to 8 membered heteroalkyl, substituted or unsubstituted C3-C8 cycloalkyl, substituted or unsubstituted 3 to 8 membered heterocycloalkyl, substituted or unsubstituted C6-C10 aryl, or substituted or unsubstituted 5 to 10 membered heteroaryl.

### Claim 9 (depends on 1)

The compound of claim 1, wherein R3 is hydrogen or unsubstituted C1-C6 alkyl.

### Claim 10 (depends on 1)

The compound of claim 1, wherein L4 is a bond, —C(O)—,
—C(O)O—, —OC(O)—, —O—, —S—, —NH—, —C(O)NH—, —NHC(O)—, —NHC(O)O—, —OC(O)N H—,
—NHC(O)NH—, —S(O)2—, —NHS(O)2—, —S(O)2NH—, substituted or unsubstituted C1-C8 alkylene, substituted or unsubstituted 2 to 8 membered heteroalkylene, substituted or unsubstituted C3-C8 cycloalkylene, substituted or unsubstituted 3 to 8 membered heterocycloalkylene, substituted or unsubstituted C6-C10 arylene, or substituted or unsubstituted 5 to 10 membered heteroarylene.

### Claim 11 (depends on 1)

The compound of claim 1, wherein L4 is a bond, —S—, —NH—, or substituted or unsubstituted 2 to 8 membered heteroalkylene.

### Claim 12 (depends on 1)

The compound of claim 1, wherein R4 is substituted or unsubstituted C1-C8 alkyl, substituted or unsubstituted 2 to 8 membered heteroalkyl, or substituted or unsubstituted C3-C8 cycloalkyl.

### Claim 13 (depends on 1)

The compound of claim 1, wherein -L4-R4 is —SCH3,

### Claim 14 (depends on 1)

The compound of claim 1, having the formula:

### Claim 15 (depends on 1)

A pharmaceutical composition comprising the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

### Claim 16 (depends on 15)

The pharmaceutical composition of claim 15, further comprising an epigenetic inhibitor.

### Claim 17 (depends on 16)

The pharmaceutical composition of claim 16, wherein the epigenetic inhibitor is an HDAC inhibitor, and wherein the HDAC inhibitor is vorinostat or romidepsin.

### Claim 18 (depends on 1)

A method of treating cancer in a subject in need thereof, said method comprising administering to the subject a therapeutically effective amount of the compound of claim 1, or a pharmaceutically acceptable salt thereof.

### Claim 19 (depends on 18)

The method of claim 18, wherein said cancer is lymphoma, leukemia, multiple myeloma, prostate cancer, breast cancer, bladder cancer, liver cancer, lung cancer, ovarian cancer, glioblastoma, pancreatic cancer, renal cancer, head and neck cancer, colon cancer, or melanoma.

### Claim 20 (depends on 18)

The method of claim 18, further comprising administering a therapeutically effective amount of an HDAC inhibitor, wherein the HDAC inhibitor is vorinostat or romidepsin.
